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Ginger (Zingiber officinale Roscoe) has been used as a spice and as a traditional remedy since ancient times,
especially in traditional Chinese medicine. It has been applied as a treatment for many diseases either alone
or in combination with other remedies. Many studies were conducted on ginger and its constituents and
a wide array of bioactivities were reported, e.g., antioxidant, anti-inflammatory, antiemetic, and
anticancer activity. Most of these had been correlated to gingerols and shogaols, the most abundant
secondary metabolites in ginger. This inspired several research groups to explore the biomedical value of
the chemical space around these compounds, and many of their synthetic or semi-synthetic analogues
have been prepared and studied for various bioactivities. Thanks to this, many valuable structure activity
relationships have been revealed for such compounds. Herein, we provide a brief summary on the
synthetic derivatization efforts that had so far been implemented on 6-gingerol, the main constituent of
fresh ginger. This review covers 160 natural, semisynthetic, or synthetic 6-gingerol derivatives and their
reported bioactivities.Introduction
Ginger, Zingiber officinale Roscoe (Zingiberaceae) is widely
renowned and has been historically used for culinary and
medicinal purposes.1,2 The roots of this plant have been used as
a herbal remedy for the prevention and/or treatment of nausea
and vomiting, diarrhea, abdominal discomfort, headache, rheu-
matism and respiratory illnesses (e.g. common cold),2 and have
also been studied for a wide range of bioactivities including anti-
inammatory, antioxidant,3 antimicrobial,4 antidiabetic,5 antihy-
pertensive, cardioprotective,6 neuroprotective,7 anti-obesity,8 anti-
migraine,9 and anticancer effects.2,10 Most recently, ginger gained
a signicant public attention when it was also suggested as
a natural home remedy that may help against COVID-19,11–13 and
even though at this time this is by no means an evidence-based
use,14 the anti-inammatory effect of ginger may hold some
promise in the relief of respiratory symptoms connected to the
SARS-CoV-2 infection.15
A wide array of bioactive compounds have been identied in
ginger such as phenolic compounds and terpenes; these have
recently been reviewed.2 Among these constituents, the so-called
gingerols are present in by far the most signicant amount in
ginger (23–25%), and this is accompanied by relatively lower levelsy Excellence Centre, University of Szeged,
ail: hunyadi.a@pharmacognosy.hu; Tel:
m, 1996, Khartoum, Sudan
ts, University of Szeged, Eötvös str. 6, H-
thors.
the Royal Society of Chemistryof other, related compounds such as shogaols and paradols.10,16,17
The main compound in the gingerol series, 6-gingerol (Fig. 1) is
partially responsible for the strong pungent taste of ginger. This
compound has been correlated with many bioactivities of ginger,
and it is present in much higher amounts in fresh ginger roots
compared to the dried roots because drying converts it into 6-
shogaol through a water elimination.16,18
Much research has been devoted to the biomedical value of
6-gingerol and its semisynthetic derivatives, and several clinical
trials had been performed using ginger extract and its constit-
uents, and some of these are still in progress. The high interest
in ginger is shown well by the fact that searching the term
“ginger” in Scopus gives over a thousand hits only for the year
2020. There are many recent reviews on ginger constituents and
their potential therapeutic applications.2,10,16,18,19 However, to
the best of our knowledge, currently no reviews are available on
the semi- and total-synthetic efforts to explore the biomedical
value of the chemical space around 6-gingerol, i.e. the medic-
inal chemistry inspired by this compound. Therefore, the aim of
this paper is to provide such a coverage with a hope that it may
draw a roadmap for further possible structural manipulationsFig. 1 The structure of 6-gingerol, i.e. 5-hydroxy-1-(4-hydroxy-3-
methoxyphenyl)decan-3-one.

































































































View Article Onlineof 6-gingerol towards new promising lead compounds based on
this simple but versatile bioactive natural product.Review scope and coverage
The information included in this review is based on papers
collected from a search in four online databases: PubMed,
Scopus, Embase and SciFinder, with no time limits, while
limiting the language to English and the search domain to title,
abstract and keywords. The search strategy included different
combinations of the following keywords: (“Ginger” OR “gin-
gerol”) AND (“semisynthetic derivative(s)” OR “synthetic deriv-
ative(s)” OR “semisynthetic analog(s)” OR “synthetic analog(s)”
OR “semisynthetic analogue(s)” OR “synthetic analogue(s)” OR
“analogs” OR “derivatives” OR “semisynthetic” OR “synthetic”
OR “synth*”). The wild-card term “*” was used to increase the
sensitivity of the search. The search in SciFinder database was
conducted as a sub-structure search using 6-gingerol structure
to access publications reporting related synthetic or semi-
synthetic work. The hits from the four databases together with
the Cochrane Library returned no review papers in the subject
of the current review.
This paper aims to provide an as complete as possible
coverage of reports dealing with semisynthetic derivatives
prepared from 6-gingerol regardless of its origin (i.e. isolated
from ginger roots or prepared by total synthesis). Some diary-
lheptanoids are included if they were not the focus of the
referred publication, e.g. if they are mentioned as compounds
synthesized together with other gingerol derivatives. The same
applies for derivatives of 8- and 10-gingerol, shogaol, zingerone,
and other ginger constituents.
When presenting chemical structures in the following
sections, the therapeutic aim was taken as the primary orga-
nizing principle. In the descriptive text, semi- and total-
synthetic gingerol analogues are presented aer a brief over-
view on the current knowledge about ginger and ginger
constituents, particularly 6-gingerol, in relation to the targeted
bioactivities.Anticancer analogues
A growing body of research suggests the possibility for the use of
ginger in cancer prevention and treatment. Ginger extract was
claimed to have promising activity against various types of
cancer (e.g. oral squamous cell carcinoma,20 chronic myeloid
leukemia,21 lung cancer22 etc). It was also studied for reducing
chemotherapy-induced nausea and vomiting.23–25
A number of biochemical pathways were implied in the
possible anticancer activity of ginger and its constituents.16,26 6-
Gingerol was reported to induce cell cycle arrest and exert anti-
invasive and apoptosis promoting effects through acting on
multiple signaling pathways in different types of cancer cell
lines.27–29 This seems to be at least partially connected to the
antioxidant–prooxidant properties of 6-gingerol. This
compound was reported to induce reactive oxygen species (ROS)
generation leading to DNA damage in cancer cells.18 It is also of
interest that gingerol was found to have antioxidant and26688 | RSC Adv., 2021, 11, 26687–26699chemopreventive activity through modulating nuclear factor
erythroid 2-related factor 2 (Nrf2);30,31 this transcription factor is
considered as a master switch in cellular antioxidant defense
and redox signaling, and has implications as a potential anti-
tumor target.32–34 Unsurprisingly, the anticancer effect of gin-
gerol appears to be the result of a multitarget action. According
to a most recent review on this subject, transcription factors
(NF-kB, activator protein-1; AP-1), b-catenin, mitogen activated
protein kinases (MAPK), growth factor receptors (EGFR, VEGFR)
and pro-inammatory mediators (COX-2, TNFa) were reported
to contribute to the anticancer activity exerted by this
compound.35
A series of clinical trials were conducted to evaluate the
possible efficacy of a 50% aqueous ethanol extract of ginger
roots (normalized to 5% of total gingerols) in preventing colo-
rectal cancer (CRC). Results from a pilot, randomized controlled
trial in patients with high risk of developing colorectal cancer
suggested that this extract may increase apoptosis and differ-
entiation and reduce proliferation of normal-appearing colon
mucosa cells.36 Increased eicosanoid, and mainly prostaglandin
E2 (PGE2) level is a marker of early stages of CRC development.
Consumption of ginger root extract was found to decrease
cycloxygenase-1 (COX-1) expression and consequentially lower
PGE2 levels in people with increased risk of developing colo-
rectal cancer (CRC) but not in participants with normal risk,37
and similar results were found in a phase II clinical study on the
PGE2 levels in the colon mucosa of healthy people at normal
risk for developing CRC.38 The PGE2-decreasing activity was
later not conrmed in volunteers with increased CRC risk,
which certainly does not rule out chemopreventive action
through other mechanisms.39
The apparent antitumor potential of ginger inspired several
research groups to take 6-gingerol as a lead compound aiming
at various bioactivities with a special emphasis on cancer. Based
on our literature survey, 160 compounds have been synthesized,
some of which are naturally present in ginger; these compounds
are discussed hereinaer.Gingerol derivatives with antiproliferative and/or cytotoxic
activity
De Lima Silva et al. recently reported the synthesis of 6-gingerol
derivatives, its O-propargyl ether (1) and several compounds
where this moiety was transformed to a 1,2,3-triazol linker to
a second phenolic ring (2–8). The compounds were tested on
colon adenocarcinoma (HCT-116) and breast metastatic
adenocarcinoma (MCF-7) cell lines. The propargyl substitution
(1) did not inuence the effect of 6-gingerol on cell viability,
however, most of the triazole derivatives exerted somewhat
increased activity that was the strongest in case of the meta-
bromine-substituted compound 8. This was still moderate, i.e.
ca. 87% and 71% inhibition in MCF-7 and HCT-116 cell lines,
respectively, at 50 mM concentration, while these values were
37% and 36% for 6-gingerol. The cells were much more sensi-
tive to the positive control doxorubicin (IC50 ¼ 0.5 and 1.9 mM

































































































View Article OnlineAnother study introduced different changes in the skeleton
of 6-gingerol (compounds 9–14, 17 i.e. 6-shogaol, 19, and 22–
24), with the aim of understanding the structure activity rela-
tionships (SAR) concerning cytotoxicity of these compounds
against MCF-7 breast cancer cells. Among these compounds,
only a 4-allyloxy derivative (10) showed higher inhibitory activity
against MCF-7 cells (IC50 ¼ 21 mM) as compared to 6-gingerol
(IC50 ¼ 30.3 mM). While these values seem to indicate moderate
activity, the same experimental setup resulted in unusually high
IC50 values for the positive controls doxorubicin and 5-uoro-
uracil (IC50 ¼ 120 mM and 158.5 mM, respectively, aer 72 h
incubation), whichmay suggest the involvement of an unknown
resistance mechanism in the cells line used. Through
comparing different substitution patterns, the authors claimed
that the aromatic ring and a free hydroxyl group on the aliphatic
side chain are important for the activity against breast cancer. It
was also noted that the length of the alkyl side chain is optimal
for this activity. Dehydrated products of 6-gingerol and its
analogue 11 (compounds 17 and 14, respectively) showed lower
inhibitory activity compared to 6-gingerol. Further, a surprising
opposite activity was found for the dimerization product of 6-
gingerol (24) that exerted a concentration-dependent increase
in cell viability.41
Another semi-synthetic effort yielded compound 25 that was
cytotoxic on triple negative breast cancer (TNBC) cell line MDA-
MB-231 (IC50 ¼ 22.9 mM aer 48 h incubation), whereas 6-gin-
gerol was technically inactive (IC50 ¼ 404.5 mM). The mecha-
nism of action was postulated to be the induction of early
autophagy, in addition to a signicant increase in ROS levels
leading to caspase-independent cellular death at later periods of
the incubation. When comparing the cytotoxicity of 25 on MDA-
MB-231 to that on a non-tumorigenic epithelial cell line MCF-
10A, a mild selectivity was found (IC50 ¼ 26.13 and 40.46 mM,
respectively, aer 24 h incubation). Further, compound 25 also
inhibited migration and invasion of TNBC cells, caused cell
cycle arrest at the G1-phase, and promoted apoptosis.42,43
An interesting hybrid molecule of 6-gingerol and acetylsali-
cylic acid (46) was synthesized by Zhu et al. with an aim to
combine the chemo-preventive and gastroprotective effect of
the former with the anti-inammatory activity of the latter, and
to simultaneously counteract the well-known gastric irritative
action of Aspirin. In vitro, compound 46 showed superior
activity as compared to the two compounds alone or in
combination, and it exerted protective effect against acute
gastric ulceration in mice, suggesting that the hybrid could
potentially be used as a multitarget chemo-preventive agent
against gastrointestinal malignancies.44Gingerol derivatives with LTA4H inhibitory activity
Leukotriene A4 hydrolase (LTA4H), a bifunctional metal-
loenzyme with aminopeptidase and epoxide hydrolase activi-
ties, plays an important role in chronic inammation
associated with carcinogenesis.45,46 Badria et al. reported the
synthesis and LTA4H inhibitory activity of natural and semi-
synthetic gingerol derivatives (9–17, and 19–24). Compound 11,
a prenylated gingerol derivative, demonstrated the strongest© 2021 The Author(s). Published by the Royal Society of Chemistryactivity against both functions of the enzyme (aminopeptidase:
IC50 ¼ 3.0 mM, epoxide hydrolase: IC50 ¼ 7.3 mM) followed by
methylshogaol (16; aminopeptidase: IC50 ¼ 4.9 mM, epoxide
hydrolase: IC50 ¼ 11.3 mM).47 Concerning the cytotoxicity of
these compounds against HCT-116 colorectal cancer cells,
compound 16 was the most effective (IC50 ¼ 1.5 mM), much
more potent than the positive controls used in the study
(betastin and 4-(4-benzylphenyl)-thiazol-2-amine (4BSA) with
IC50 ¼ 42.5 and 30.5 mM, respectively). 6-Shogaol (17) itself was
less potent (IC50 ¼ 12.9 mM) than compound 16, i.e. the ortho-
dimethoxy group in the aromatic ring increased the cytotoxic
activity by nearly an order of magnitude. The same increase in
efficacy was, however, not observed when 6-gingerol was simi-
larly methylated to compound 19 (IC50 ¼ 76.5 mM), which
highlights the importance of the enone group in the side chain
for this bioactivity. The compounds showed no toxicity to
normal cells, and several of them had high selectivity towards
HCT-116 cells as compared to normal TIG-1 cells: the selectivity
index was over 52 in case of the most potent compound 16.47Gingerol derivatives with antioxidant and/or HDAC inhibitory
activity
In the last two decades, histone deacetylase (HDAC) enzymes
have been emerging as anticancer targets.48 In 2019, A combi-
nation of tucidinostatin, an HDAC enzyme inhibitor, and
exemestane, an aromatase enzyme inhibitor was studied in
a randomized, double-blind, placebo-controlled, phase III trial
on postmenopausal patients with advanced hormone receptor-
positive breast cancer, and encouraging results were reported.49
A link between the HDAC inhibitory activity and ROS levels had
been highlighted. A suggested mechanism for HDAC inhibitors
in cancer is through increasing intracellular ROS levels and
downregulating antioxidant pathways resulting in increased
level of DNA damage,50 and the ability to repair this damage is
impaired in cancer cells.51 In connection to this, it is of interest
that many plant-originated phenolic antioxidants have been
reported as HDAC inhibitors.52–54
The anticancer activity of natural and semi-synthetic 6-gin-
gerol derivatives (9, 17, 18 and 26–29, (3R,5S)-30 and 31–39), was
studied through assessment of their HDAC enzyme inhibition
and antioxidant activity by Kunboonma et al. All these
compounds showed HDAC inhibitory activity in the micromolar
concentration range, and compound 29 was the most active
among all (IC50 ¼ 42 mM). Compound 18, a demethylated 6-
shogaol derivative was the most potent semi-synthetic
compound (IC50 ¼ 45 mM; compared to 61 mM for gingerol),
a role of the catechol moiety was suggested for the increase in
activity as compared with that of 6-shogaol itself. In case of
compounds 31–39, the oxime orientation did not inuence the
bioactivity. When testing the compounds by the DPPH (2,2-
diphenyl-1-picryl-hydrazyl-hydrate) scavenging assay, most of
the investigated derivatives (except compounds 28, (3R,5S)-30,
and 38), showed higher antioxidant activity compared to 6-
gingerol (IC50 ¼ 81 mM) but lower than the applied positive
control, gallic acid (IC50 ¼ 37 mM), and 35 and 38 were the most

































































































View Article Online58 mM) was reported to exert the highest antioxidant activity.
Furthermore, based on in silico docking studies it was suggested
that compounds 17, 18, and 29 may serve as promising anti-
HDAC leads with different isoform selectivity. Nevertheless,
the reported activities were still moderate and the compounds
would require further structural optimization to exert pharma-
cologically relevant HDAC inhibitory effect.55
Inuence of the length and structure of the side chain on the
antioxidant properties of 6-gingerol was studied on its
analogues 17 and 40–45. Four experimental models were used
including DPPH scavenging, ferric reducing antioxidant power
(FRAP), DNA strand breakage inhibition and human red blood
cell haemolysis protection. Regarding DPPH scavenging
activity, shogaols were found the most effective, followed by
gingerols, while dehydrogingerols and dehydroshogaols were
the least effective; therefore, the C4–5 double bond may have
a role in boosting the activity. Increasing the side chain length
had no remarkable effect on the DPPH scavenging activity,
however in case of FRAP measurements it had a negative effect
on the potency. Increasing the side chain length signicantly
decreased the DNA strand breakage ability, while enhanced the
anti-haemolysis activity. Thus, it was concluded that the anti-
oxidant activity largely depends on the side chain.56
Altogether, concerning the antitumor potential of gingerol
derivatives, the currently known compounds are not very cyto-
toxic, still, they seem to have antitumor potential due to their
abilities to interfere with several pathways relevant to antitumor
drug discovery. This concerns mainly the chemo-preventive
potential of the semi-synthetic derivatives, similarly to the
inspiring compound 6-gingerol itself. Nevertheless, the potent
and selective cytotoxic activity of compound 16 against colon
cancer cells suggests that related analogues may also be devel-
oped with a potential to ght the already developed disease.Anti-inflammatory gingerol analogues
The anti-inammatory effect of ginger is among its most deeply
studied medicinal properties. The effects of ginger were studied
against many inammatory conditions in human subjects,
including knee osteoarthritis57,58 joint pain,59 and obesity as
a risk for cardiovascular complications.60 The anti-
inammatory effect of ginger supplementation was studied on
subjects who are free of any inammatory conditions and at
varying degree of exercise levels (NCT03219463). Aer ginger
consumption a drop in the levels of inammatory biomarkers
tumor necrosis factor a (TNF-a) and interleukin-6 (IL-6) was
reported. Therefore, it had been concluded that ginger may
serve as a potential adjuvant to prevent diabetes, heart diseases
and other chronic disorders connected to inammation. Ginger
consumption was also reported to reduce inammatory medi-
ators C-reactive protein (CRP) and interleukin-1b (IL-1b) in
patients with rheumatoid arthritis (RA),61 and 6-gingerol was
reported to inhibit sepsis development through interfering with
pro-inammatory cytokines' secretion and attenuating pyrop-
tosis in macrophages,62 i.e., an inammatory-type programmed
cell death.6326690 | RSC Adv., 2021, 11, 26687–26699These ndings on ginger inspired the synthesis of several 6-
gingerol analogues aiming to develop new anti-inammatory
agents. A set of natural and semi-synthetic ginger constitu-
ents, i.e., compounds 17, 20, 21, 42 (Fig. 2), and compounds 47–
58 (Fig. 3) were studied for their cyclooxygenase-2 (COX-2)
inhibitory activity in intact A549 cells that are known to
express this enzyme. Compound 56 was found to be the most
active (IC50 ¼ 1.4 mM) among these compounds, followed by
compounds 17, 58, 47, 8-paradol (21), 10-gingerol (57), and 49
that was still active with an IC50 value of 5.5 mM. All other
compounds showed moderate activity, and 6-gingerol itself did
not reach 50% inhibition at up to 50 mM. Concerning SAR, an
aromatic group substituted with a free hydroxyl group at C3 or
C4 was found important for a potent COX-2 inhibition:
compound 53 with the hydroxyl group at C2 of the aromatic ring
and compound 50 with methoxy-substituents at both C3 and C4
showed only moderate activity (IC50 > 50 mM). Also, importance
of the length of the alkyl chain was highlighted, and a 14-C
length was suggested as the optimum. A signicant increase in
the activity was observed with a hydroxyl group on the alkyl
chain, while replacement of the carbonyl group with a hydroxyl
group had no remarkable effect on the potency of compounds,
as in, e.g., compound 54 (IC50 ¼ 12.5 mM) compared with
compound 20, i.e., 8-gingerol (IC50 ¼ 10 mM). Nevertheless,
reduction of the carbonyl group to a methylene boosted the
activity as in compound 56 (IC50 ¼ 1.4 mM).64
Anti-inammatory activity of two racemic gingerol deriva-
tives, a stable metabolite of 6-gingerol (58), and another deriv-
ative named Capsarol (49), joining some molecular properties
of gingerol and capsaicin, were evaluated as possible anti-
inammatory agents by Aktan et al. The compounds were
tested for their effect on inducible nitric oxide synthase (iNOS)
and found to suppress NO production in murine macrophages
through a partial inhibition of the enzyme and by simulta-
neously decreasing iNOS expression through its NF-kb-medi-
ated transcriptional regulation.65
As seen from the above examples, the anti-inammatory
activity of 6-gingerol analogues seems to be encouraging to
further studies that may have a chance for the development of
a suitable anti-inammatory drug candidate in the future.Antimicrobial gingerol analogues
The potential antibacterial activity of ginger was also assessed.
Ginger extract showed activity against dental caries-causing
bacteria; Streptococcus mutans and S. sanguinis with minimum
inhibitory concentration (MIC) values of 20 and 300 mg ml1,
respectively, and it was suggested that this activity may be
attributed to gingerols.66 In another, in vitro and in vivo study on
the effect of ginger on S. mutans bacteria, ginger extract
inhibited bacterial growth with MIC ¼ 256 mg ml; differences in
MIC values might be attributed to different experimental
conditions and/or extraction method. Glucan synthesis, bacte-
rial adhesion, and biolm formation were also reduced in vitro,
and a reduction of caries development was observed in ginger-
treated rats versus the control group.67© 2021 The Author(s). Published by the Royal Society of Chemistry

































































































View Article OnlineComponents of ginger were investigated for anti-virulence
and antibiolm activities against a uconazole resistant
Candida albicans strain. It was reported that 6-gingerol, 8-gin-
gerol and 6-shogaol effectively inhibited biolm formation.
Furthermore, 6-gingerol and 6-shogaol also reduced virulence
of the fungus.68
Gingerol analogues including 6-gingerol and 6-shogaol were
also studied for their antibacterial activity against a range of© 2021 The Author(s). Published by the Royal Society of Chemistrymulti-drug resistant bacteria. Plasmid conjugal transfer prop-
erty was also assessed. It was concluded that the investigated
compounds are valuable antibacterial agents with an ability to
reverse horizontal antibiotic resistance spread in bacteria.69
In combination with tea polyphenols, 6-gingerol was also
reported to maintain the quality of shrimp paste during storage,
and the reduction of bacterial growth was a suggested mecha-
nism for this effect.70RSC Adv., 2021, 11, 26687–26699 | 26691

































































































View Article Online6-Gingerol was found to reduce virulence and biolm
formation of Pseudomonas aeruginosa via the inhibition of
quorum sensing (QS),71 i.e., a mechanism of bacterial cell to cellFig. 4 Semi-synthetic gingerol derivatives prepared and evaluated for th
26692 | RSC Adv., 2021, 11, 26687–26699communication that is of crucial importance in controlling
their colony-wide functions and plays an important role in their
virulence.72 In further research into the bioactivities of gingereir in vitro antibacterial activity.

































































































View Article Onlineconstituents, the antibacterial activity of 6-gingerol, 6-shogaol
(compound 17, Fig. 2), zingerone (59) and two new synthetic
analogues, namely 6-azashogaol (61) and an isoxazole derivative
of 6-gingerol (62) was assessed (Fig. 4). The antibacterial activity
of these compounds was investigated by assessing their growth
inhibitory activity on Pseudomonas aeruginosa and Chromo-
bacterium violaceum bacterial strains, and by measuring the
concentration of pyocyanin pigment produced by P. aerugi-
nosa.73 The expression of this pigment is controlled by QS.72
Compound 61 was reported to have the highest activity with the
lowest MIC against both strains and 90% reduction of pyocya-
nin pigment produced by P. aeruginosa, while zingerone (59)
was the least active. The authors highlighted that low molecular
weight compounds with long side chain are needed for anti-QS
activity which may explain the low activity of zingerone (only 4
carbons long side chain). It was also observed that the presence
of an amide linker enhances the activity, as evidenced by the
activity of compound 61, while the isoxazoline linker had only
minor inuence on the activity.73
Investigating the same pathway of QS and the possibility of
discovering new antibacterial gingerol derivatives, Choi et al.
reported the synthesis of 6-gingerol and further derivatives (19–
22, 40, Fig. 2; 47, Fig. 3; 59, 60, and 63–86, Fig. 4), some of them
naturally present in ginger root. The compounds were tested for
their binding to LasR, a transcriptional regulator protein play-
ing a major role in the processes of QS in P. aeruginosa and
biolm formation, which in turn confers virulence to the
bacteria and poses a health problem especially to immuno-
compromised patients. Bacterial inhibition was alsomonitored.
It was concluded that (R)-8-gingerol (86) and its C1–C2 unsat-
urated analogue (85) were the most promising, and the impor-
tance of stereochemistry regarding the activity against P.
aeruginosawas emphasized. At 10 mM concentration, compound
85 decreased bacterial biolm thickness from 34.5 mm (negative
control, DMSO) to 10.3 mm, which was 13.9 mm in case of
compound 86 and 17 mm for the naturally occurring (S)-8-gin-
gerol (compound 20), even though bacterial growth inhibition
was not observed for either compound even at 100 mM
concentration. The authors emphasized the importance of
rotational rigidity between the head section and the carbonyl
group for LasR-binding affinity and for inhibition of biolm
formation as evidenced by the higher activity of compound 85
as compared to that of 86. This was also supported by in silico
docking. SAR evaluation showed that an increase of the alkyl
chain length up to 12 carbons led to an increase of activity,
which may explain why 8-gingerol analogues (compounds 47,
66, 68, 70, 72, 74, 76, 78, 80, 81, 82, 85 and 86) were found to be
more active than 6-gingerol derivatives (compounds 19, 40, 67,
69, 71, 73, 75, 77, and 79). Also, it was reported that a hydrogen
bond acceptor is needed at position C4 on the aromatic ring for
a higher potency. In addition, the presence of a hydroxyl group
substituent on the alkyl chain has been correlated with higher
antibacterial activity.4
A recent study, published in 2019, reported the application
of 6-gingerol and two of its derivatives (85, 86) to reduce
biofouling in reverse osmosis water treatment systems by dis-
rupting the QS processes of P. aeruginosa. The study aimed to© 2021 The Author(s). Published by the Royal Society of Chemistrypropose effective but harmless solution to membrane
biofouling as the biocides in use may pose toxicity problems. In
accordance with the above-mentioned results reported by Choi
et al., compound 85 was the most effective in inhibiting biolm
formation followed by compound 86 and then 6-gingerol (38%,
35%, and 22% reduction in biolm formation, respectively),
while only 4% inhibition was observed for sodium hypochlorite
(NaOCl) used as a positive control in this study (only 10 mM
NaOCl concentration was used in the study for the purpose of
comparison, while its MIC is ranging between 33.6–40.3 mM).
These results were conrmed by the reduction in QS-responsive
gene expression. However, bacterial growth was not affected by
the compounds investigated.74
Anti-platelet gingerol analogues
The anti-platelet activity of ginger was also investigated, and
ginger constituents like 6-gingerol and 6-shogaol were reported
to exert potent antiplatelet activity.75,76
Shih et al. reported the synthesis of 6-gingerol and a group of
45 derivatives that are either naturally present in ginger root or
new synthetic analogues (compounds 17, 20, 21, 29, 40, and 41,
Fig. 2; 47, 48, and 51, Fig. 3; 63–65, 81, 82, and 83, Fig. 4; and 87–
116, Fig. 5), and testing these compounds for anti-platelet
aggregation activity. It was demonstrated that at 10 mg ml1
concentration most of the compounds exert an over 90% inhi-
bition of platelet aggregation induced by 100 mM of arachidonic
acid. Compounds of the paradol series (47, 51 and 103–107)
were the most active, and 6-paradol (51) showed the highest
activity (IC50 ¼ 0.070 mg ml1 compared to 1 mg ml1 for 6-
gingerol). A decrease in the activity was observed with the
introduction of a double bond (as in shogaols, or dehydropar-
adols) or a hydroxyl group (as in gingerols) into the paradol side
chain, however, increasing the alkyl side chain length increased
the activity (e.g. the dehydroparadol compound 110 showed an
IC50 value of 0.160 mg ml
1). The epoxide derivatives (111–116)
showed a lower potency compared to n-paradols (IC50 ¼ 0.96–
2.38 mg ml1). On the other hand, it was reported that the
compounds showed negligible activity against platelet aggre-
gation induced by platelet activating factor (PAF) or thrombin
(Thr), suggesting that compound 51 is a selective inhibitor.77
Koo et al. studied the effect of 6-gingerol and its synthetic
analogues (20, Fig. 2; 54, 55, Fig. 3; and 117–119, Fig. 5) on the
arachidonic acid-induced platelet serotonin release and aggre-
gation, and found lower platelet aggregation inhibitory activity
for all compounds (ICmax ¼ 10–25 mM) as compared to ace-
tylsalicylic acid (ICmax ¼ 6 mM). However, the compounds acted
in a similar dose range as Aspirin when tested on arachidonic
acid-induced platelet serotonin release. To examine the
underlying mechanism, COX-inhibitory activity of these
compounds was assessed. Compounds 55, 20, and 54 exerted
similarly potent inhibitory activity (IC50 ¼ 1.2, 1.5, and 3.3 mM,
respectively) as the positive control indomethacin (IC50 ¼ 0.76
mM), unlike 6-gingerol (IC50 ¼ 50 mM). It is worth mentioning
that the COX inhibitory activity of the compounds correlated
with their hydrophobicity, with compound 55 being the most
active and the most hydrophobic at the same time.78RSC Adv., 2021, 11, 26687–26699 | 26693

































































































View Article OnlineThe anti-platelet and COX-1 inhibitory activity were also
studied for another set of gingerol derivatives (17, 20, 21, 30, 42,
Fig. 2; and 47–49, 51, 54–58, Fig. 3; 65, Fig. 4; and 120–123,
Fig. 5). 8-Paradol (47) was reported as the most effective anti-
platelet agent among the investigated analogues (75% inhibi-
tion at 2 mM while 6-gingerol exerted 3.4% inhibition at the
same concentration). In case of compounds 47, 49 and 58 the
COX-1 inhibitory activity was also assessed through monitoring
the amount of the pro-aggregatory product thromboxane A2.
Compound 47 also exerted the highest activity and it was more
potent than aspirin under the conditions described in the study
(IC50 ¼ 4 mM vs. 20 mM). Investigations into the SAR revealed
that presence of the carbonyl function at C3 is important for
activity, any other substituents on the alkyl chain interfere with
the COX-1 inhibitory activity. This was evidenced through
comparing the activity of compound 47 with that of 49 (IC50 ¼
20 mM). No correlation between the molecular hydrophobicity
and anti-platelet aggregation activity was found in this case.79
The above-mentioned in vitro results seem to be promising
and may also point towards cardiovascular protective drug
development. Nevertheless, further research would be needed
to evaluate the in vivo efficacy and safety of gingerol analogues
to assess their potential as anti-platelet lead or candidate drugs.26694 | RSC Adv., 2021, 11, 26687–26699Miscellaneous bioactivities
Several other bioactivities were reported for ginger and its
constituents, e.g. smooth muscle relaxant, painkiller, anti-
emetic, and anti-obesity activity. Altogether, these reports
suggest a versatile pharmacology to these natural products.
Anti-emetic activity of 6-gingerol was also conrmed in a phase
II randomized double-blind placebo-controlled study in cancer
patients treated with highly emetogenic chemotherapeutic
agents.25 A recent study on rats revealed that the underlying
mechanism of action is the modulation of serotonin levels.80
Although the effect of ginger in nausea and vomiting prevention
and treatment was thoroughly studied and showed promising
results, to the best of our knowledge no related studies were
dedicated for semisynthetic derivatives of 6-gingerol.Gingerol analogues with activity on muscles' Ca2+
homeostasis
In 1988, 6-gingerol and compounds 20–22, 28, 30, 42 (Fig. 2),
and 124–131 (Fig. 6) were investigated for their effect on spon-
taneous Ca2+ spikes and contraction of portal veins isolated
from mice. Most of the tested compounds suppressed sponta-
neous contractions; however, the most promising activity was© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 6 Semi-synthetic gingerol derivatives with miscellaneous bioactivities. Compounds are presented that were prepared and evaluated for

































































































View Article Onlinefound for 6-gingerol and derivative 129. Interestingly,
compound 20 (8-gingerol) also inhibited spontaneous contrac-
tions but without affecting Ca2+ spikes. It was suggested that the
inhibition of spontaneous contraction is due to Ca2+ spike
suppression in case of 6-gingerol, while 8-gingerol acts through
a different mechanism of action. SAR evaluation revealed that
the optimal alkyl chain length for higher potency is ten carbons© 2021 The Author(s). Published by the Royal Society of Chemistry(i.e., the chain length of 6-gingerol), and the reduction of
carbonyl group on C3 of the alkyl side chain or oxidation of the
5-hydroxyl group decreases smooth muscle relaxant activity.81
Based on its stimulating activity on cardiac sarcoplasmic
reticulum (CSR) Ca2+ ATPase, 6-gingerol was reported as
a potent cardiotonic agent by Kobayashi et al., and it was also

































































































View Article Onlinetreated diabetic mouse model, this bioactivity also confers 6-
gingerol a benecial activity in diabetes-related diastolic
dysfunction.83 When studying this bioactivity for 6-, 8-, and 10-
gingerol and their derivatives (20, 21; Fig. 2, and 132–134;
Fig. 6), all the tested compounds were found to increase the SR-
ATPase activity in a concentration-dependent manner. There-
fore, it was postulated that they may play a role in Ca2+ –
pumping from the cytoplasm to the SR lumen causing skeletal
muscle relaxation, and both the hydrocarbon chain and the o-
methoxyphenol parts were postulated as necessary for the
activity.84Pain management: TRPV and TRPA modulation
Ginger has a proven painkiller activity operating via multiple
mechanisms: COX and lipoxygenase (LOX) enzymes inhibition,
inhibition of NF-kb, or acting as vanilloid receptor agonist.85
The transient receptor potential (TRP) cation channel
subfamily V, member 1 (TRPV1), and subfamily A, member 1
(TRPA1) are known for their integral role in pain and neuro-
genic inammation. Recent studies revealed that TRP channels
are crucial in other physiological and pathological conditions,
like cancer, cardiac health, and renal physiology. However, their
precise function in vivo is still yet to be revealed.86–88
In 2007, inspired by the activity of the oleyl moiety on TRPV1
receptor,89 the synthesis of related gingerol and shogaol
analogues (oleylgingerol; 135, and oleylshogaol; 136) was re-
ported. When testing TRPV1 activating effect of 6-gingerol and
its derivatives (17, 20, 21; Fig. 2, 48; Fig. 3, 101; Fig. 5, 135 and
136; Fig. 6), all compounds showed higher activity (EC50 ¼ 0.26–
4.17 mM) than 6-gingerol (EC50 ¼ 4.55 mM) but lower than the
positive control capsaicin (EC50 ¼ 0.082 mM). Oleylgingerol was
the most active, while oleylshogaol the least active of them,
suggesting that the 5-hydroxyl group has a signicant role in
activating the TRPV1 channel.90
To explore the chemical space around 6-gingerol concerning
its potential for vanilloid receptor modulation, Morera et al.
reported the synthesis of racemic 6-gingerol analogues (17;
Fig. 1, 67, 75; Fig. 4 and 137–152; Fig. 6) and their biological
evaluation on TRPV1 and TRPA1 channels.91 With regard to the
activity on TRPV1, compound 141 exerted the highest potency
and selectivity among all (EC50 ¼ 0.11 mM, compared to 3.3 mM
for 6-gingerol), whereas compounds 138, 144, and 145, each
containing two isopropyl groups in ortho position to the
phenolic hydroxyl group, were found to be inactive. This indi-
cates that steric hindrance around the phenolic hydroxyl func-
tion negatively affects the activity. Further studies into the SAR
showed importance of the phenolic hydroxyl group and noted
an increase in activity with the increase in molecular lip-
ophilicity. The free hydroxyl group on the side chain was found
to be of less importance as proved by the efficacy of 6-shogaol
(17) and its analogue (152) on TRPV1 channels. On the contrary,
activity on TRPA1 channels was the highest in case of
compound 139, with favoured branched alkyl substituents at
the ortho position to the phenolic hydroxyl group. It is note-
worthy that compounds 17, 141 and 151 acted as selective26696 | RSC Adv., 2021, 11, 26687–26699TRPV1 agonists, while compounds 143, 144, 146, and 147 were
selective TRPA1 antagonists.91Antidiabetic and antihepatotoxic activities
Results from a randomized clinical trial on the possible anti-
diabetic potential of ginger consumption suggested a decrease
in blood glucose and cholesterol levels.92
Moreover, synergistic effect of 6-gingerol and quercetin was
investigated in streptozotocin-induced type 2 diabetes and
poloxamer P-407 induced hyperlipidaemia on rats. The combi-
nation treatment was found to exert remarkable antidiabetic
and benecial cardiac effects, and the synergism was suggested
to occur through the modulation of serotonergic system.93
In metabolic syndrome, the prophylactic effect of 6-gingerol
and its synthetic analogue aza-6-gingerol (153) was investigated
on high fat diet-fed type 2 diabetic mice. Both compounds
caused a reduction of lipogenic genes, which was postulated to
occur through downregulation of sterol regulatory element-
binding protein 1c (SREBP-1c), a protein that is responsible
for regulating the transcription of many lipogenic genes.
Compound 153 was found more effective than 6-gingerol in
enhancing metabolism and reducing the extent of lipogenesis.
It was suggested that compound 153 might possess potential
therapeutic value to reduce the risk of obesity-associated
diseases, however, further studies are needed to uncover the
underlying mechanism of action.94
Liu et al. reported the repressive activity of 6-gingerol on
nutritional steatohepatitis induced in mice. The protective
effect was postulated to occur due to regulation of key genes
related to oxidative stress, inammation and brogenesis.95
Antihepatotoxic effects of gingerols and shogaols on carbon
tetrachloride- and galactosamine-induced cytotoxicity in
primary cultured rat hepatocytes were also studied. Compounds
17, 20–22, 28–30, 42, 43 (Fig. 2), 48 (Fig. 3), 59 (Fig. 4), 100–102
(Fig. 5), 124, 126, and 154–160 (Fig. 6) were evaluated, and both
gingerols and shogaols were found to exert anti-hepatotoxic
actions, with gingerols being superior in this regard. Studies
into the SAR revealed importance of the side chain length with
the highest activity achieved with (7) and (8)-congeners.
Reduction of the carbonyl group on the side chain, oxidation of
the 5-hydroxyl group, or introduction of a double bond into the
side chain were found to decrease the activity of gingerols.96Conclusions
6-Gingerol, the main constituent of Zingiber officinale (Zingi-
beraceae) has been extensively studied in the last century for its
potential anti-inammatory, antioxidant, antimicrobial and
anticancer effects. Several clinical studies have been performed
and some are currently in progress to conrm these observa-
tions. The benecial activities of ginger inspired several
research groups to explore the chemical space around 6-gin-
gerol: chemical modications have led to numerous derivatives
interfering with multiple cellular pathways leading to improved
anticancer, anti-inammatory, antimicrobial anti-platelet, and/

































































































View Article Onlineshow serious potential to drug discovery, concerning their sub-
micromolar efficacy as anti-inammatory and/or antiplatelet
agents, or vanilloid receptor agonist. Nevertheless, in vivo
studies are missing for many of these compounds so that their
efficacy and safety prole could be better evaluated, and to the
best of our knowledge none of the semi-synthetic derivatives of
gingerol reached a clinical trial until now. Therefore, there is
still much to learn on the true drug discovery potential that can
be attributed to the chemical space surrounding this relatively
simple, but versatile natural product, 6-gingerol.
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